Bioline Rx Common Stock

Bioline Rx (BLRX) currently reports a common stock of $73M as of March 2026. That compares with $63M in the prior-year period — up 17.4% year over year. Use the charts on this page to explore Bioline Rx's common stock history and peer comparisons.

Bioline Rx's common stock increased from $63M to $73M — a 17.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bioline Rx reported $73M in common stock as of March 2026. That compares with $63M in the prior-year period — up 17.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $73M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bioline Rx, and consider following BLRX for alerts when major investors trade the stock.

Bioline Rx is classified in the Healthcare sector. On common stock, it currently shows $73M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLRX with unrelated industries.